RSV patients treated with antiviral drug S-337395 showed statistically significant reduction in viral load S-337395 is ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 trial. The study saw 114 healthy adults inoculated with the virus and ...

LONDON - Shionogi & Co., Ltd. (TYO ... oral antiviral candidate targeting Respiratory Syncytial Virus (RSV), conducted by hVIVO plc, a leader in human challenge clinical trials.

GlobalData is the parent company of Clinical Trials Arena. Elsewhere in the RSV treatment market, Japanese company Shionogi’s oral antiviral for RSV has met its primary endpoint in a Phase II ...

R&D expenses increased 9.4% year-over-year, reflecting aggressive investment in high-priority development pipelines, including clinical trials for COVID-19 and RSV-related treatments. Hidemaru ...